First-line rituximab for pemphigus associated with long-term complete remission rates

1. Patients with pemphigus treated with first-line rituximab showed sustained complete remission rates without corticosteroids for up to 7 years post-treatment 2. High-risk patients for pemphigus relapse could be assessed with enzyme-linked immunosorbent assay (ELISA) values of anit-Dsg antibodies. Evidence Rating Level: 1 (Excellent) Study Rundown: Pemphigus is a life-threatening rare autoimmune bullous disease affecting […]

The post First-line rituximab for pemphigus associated with long-term complete remission rates first appeared on 2 Minute Medicine.